AB
Andrew Brackmann
Compare →Former Equity Research Analyst at William Blair ·; Current Vice President of Investor Relations at NeoGenomics
Financial & Wall StreetHealthcare
Andrew Brackmann is a financial analyst with extensive experience in equity research, particularly in the healthcare sector. He worked at William Blair for nine years, where he focused on medical technology companies before transitioning to NeoGenomics as Vice President of Investor Relations.
No chart yet. A chart needs 8 resolved predictions, and Andrew has 6. The predictions themselves are below.
SORT
STILL OPEN
?
NeoGenomics expects to achieve a revenue growth of 15% year-over-year in 2027.
own side · their own organization · shown, counts only if it does not happen
Due Dec 31, 2027July 28, 2026FinanceEarningsPending
—
SCORE
?
Andrew Brackmann assigned a price target of $205.00 for Quest Diagnostics.
April 21, 2026StockPrice TargetPending
—
SCORE
?
Natera will be rated as Outperform.
April 14, 2026Stock RatingPending
—
SCORE
?
Exact Sciences will be downgraded to Market Perform.
November 21, 2025Stock RatingPending
—
SCORE
RESOLVED · NEWEST FIRST
✓
Andrew Brackmann reiterated a hold rating for Qiagen with a price target of $38.00.
April 28, 2026call #6StockPrice TargetCorrect
82
SCORE
✓
CareDx will outperform the market.
August 26, 2025call #5HealthcareStock RatingCorrect
82
SCORE
◇
Sign in to read this call.
February 12, 2025Stock RatingNot settleable
—
SCORE
✓
Tempus AI will outperform the market.
July 9, 2024call #4HealthcareStock RatingCorrect
82
SCORE
✓
QuidelOrtho will underperform the market.
February 14, 2024call #3HealthcareStock RatingCorrect
85
SCORE
◇
Sign in to read this call.
March 24, 2023healthcarereimbursementNo verdict
—
SCORE
◇
Reimbursement for Select MDx test is estimated at $760 per test if it passes a technical assessment by the MolDx program.
March 24, 2023healthcarereimbursementNo verdict
—
SCORE
✓
Covered lives figures for MDxHealth's tests will expand modestly in the future.
March 24, 2023call #2healthcarereimbursementCorrect
75
SCORE
✗
Sign in to read this call.
February 3, 2022call #1HealthcareStock RatingWrong
0
SCORE
Still open · 4
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
NeoGenomics expects to achieve a revenue growth of 15% year-over-year in 2027.
Due Dec 31, 2027Said July 28, 2026FinanceEarnings
?No market prices this claim
Andrew Brackmann assigned a price target of $205.00 for Quest Diagnostics.
Said April 21, 2026StockPrice Target
?No market prices this claim
Natera will be rated as Outperform.
Said April 14, 2026Stock Rating
?No market prices this claim
Exact Sciences will be downgraded to Market Perform.
Said November 21, 2025Stock Rating